Atherosclerosis
Volume 169, Issue 1 , Pages 63-70 , July 2003

Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism

Received 25 August 2002 ,Revised 14 February 2003 ,Accepted 3 April 2003.

References 

  1. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 1991;266:18259–18267
  2. Clavey VS, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler. Thromb. Vasc. Biol. 1995;15:963–971
  3. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 1990;265:10771–10779
  4. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 1990;265:22453–22459
  5. Jong MC, van Dijk KW, Dahlmans VE, van der Boom H, Kobayashi K, Oka K, et al. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem. J. 1999;338:281–287
  6. Gautier T, Masson D, de Barros J-PP, Athias A, Gambert P, Aunis D, et al. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. J. Biol. Chem. 2000;275:37504–37509
  7. Buchko GW, Rozek A, Kanda P, Kennedy MA, Cushley RJ. Structural studies of a baboon (Papio sp.) plasma protein inhibitor of cholesteryl ester transferase. Protein Sci. 2000;9:1548–1558
  8. Jong MC, Voshol PJ, Muurling M, Dahlmans VE, Romijn JA, Pijl H, et al. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes. 2001;50:2779–2785
  9. Simonet WS, Bucay N, Pitas RE, Lauer SJ, Taylor JM. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J. Biol. Chem. 1991;266:8651–8654
  10. Shachter NS, Ebara T, Ramakrishnan R, Steiner G, Breslow JL, Ginsberg HN, et al. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein CI. J. Clin. Invest. 1996;98:846–855
  11. Jong MC, Gijbels MJJ, Dahlmans VEH, van Gorp PJJ, Koopman S-J, Ponec M, et al. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J. Clin. Invest. 1998;101:145–152
  12. Holmquist L. Quantitation of human serum very low density apolipoproteins C-I, C-II, C-III and E by enzyme immunoassay. J. Immunol. Methods. 1980;34:243–251
  13. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of apolipoproteins C-I and C-II in human plasma by separate electroimmunoassays. Clin. Chem. 1981;27:543–548
  14. Carlson LA, Holmquist L. Concentrations of apolipoproteins B, C-I, C-II, C-III and E in sera from normal men and their relation to serum lipoprotein levels. Clin. Chim. Acta. 1982;124:163–178
  15. Riesen WF, Sturzenegger E. Enzyme-linked immunosorbent assay for apolipoprotein C-I. J. Clin. Chem. Clin. Biochem. 1986;24:723–727
  16. Wahlberg G, Holmquist L, Walldius G, Annuzzi G. Effects of nicotinic acid on concentrations of serum apolipoproteins B, C-I, C-II, C-III and E in hyperlipidemic patients. Acta Med. Scand. 1988;224:319–327
  17. Bren ND, Rastogi A, Kottke B. Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays. Mayo Clin. Proc. 1993;68:657–664
  18. Alaupovic P, Schaefer EJ, McConathy WJ, Fesmire JD, Brewer HB. Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease). Metabolism. 1981;30:805–809
  19. Annuzzi G, Holmquist L, Carlson LA. Concentrations of apolipoproteins B, C-I, C-II, C-III, E and lipids in serum and serum lipoproteins of normal subjects during alimentary lipaemia. Scand. J. Clin. Lab. Invest. 1989;49:73–81
  20. Björkegren J, Karpe F, Milne RW, Hamsten A. Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J. Lipid Res. 1998;39:1412–1420
  21. Smit M, van de Kooil-Meijs E, Woudt LP, Havekes LM, Frants RR. Exact localization of the familial dysbetalipoproteinemia associated restriction site in the promoter region of the apoC1 gene. Biochem. Biophys. Res. Commun. 1988;152:1282–1288
  22. Xu Y, Berglund L, Ramakrishnan R, Mayeux R, Ngai C, Holleran S, et al. A common HPA I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E. J. Lipid Res. 1999;40:50–58
  23. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distribution in selected North American populations: the Lipid Research Clinics Program prevalence study. Circulation. 1979;60:427–439
  24. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin–manganese precipitation procedure for estimating high density lipoprotein cholesterol. J. Lipid Res. 1978;19:65–76
  25. Hill JS, Pritchard PH. Improved phenotyping of apolipoprotein E: application to population frequency distribution. Clin. Chem. 1990;36:1871–1874
  26. Cohn JS, Tremblay M, Amiot M, Bouthillier D, Roy M, Genest J, et al. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 1996;16:149–159
  27. Fredenrich A, Giroux L-M, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hyperlipidemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J. Lipid Res. 1997;38:1421–1432
  28. Cohn JS, Tremblay M, Batal R, Jacques H, Veilleux L, Rodriguez C, et al. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 2002;43:1680–1687
  29. Hixson JE, Vernier DT. Restriction isotyping of human apolipoproteinE by gene amplification and cleavage with HhaI. J. Lipid Res. 1990;31:545–548
  30. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1–21
  31. Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler. Thromb. 1994;14:1105–1113
  32. Smit M, de Knif P, Rosseneu M, Bury J, Klasen E, Frants R, et al. Apolipoprotein E polymorphism in the Netherlands and its effect on plasma lipid and apolipoprotein levels. Hum. Genet. 1988;80:287–292
  33. Luc G, Ducimetiere P, Bard J-M, Arvelier D, Evans A, Cambien F, et al. Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype. Atherosclerosis. 1997;131:257–262
  34. Schiele F, Vincent-Viry M, Starck M, Beaud B, Hennache G, Siest G, et al. Apolipoprotein E in apolipoprotein B (apo B)- and non-apo B-containing lipoproteins in 3523 participants in the Stanislas Cohort: biological variation and genotype-specific reference limits. Clin. Chem. 2002;48:291–300
  35. Mak PA, Laffitte BA, Desrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, Tontonoz P, Edwards PA. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages; a critical role for the nuclear receptors LXRalpha and LXRbeta, J Biol Chem 2002;277:31900–8.
  36. Allan CM, Walker D, Taylor JM. Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus. Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice. J. Biol. Chem. 1995;270:26278–26281
  37. Allan CM, Walker D, Segrest JP, Taylor JM. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Genomics. 1995;28:291–300
  38. Shih SJ, Allan C, Grehan S, Tse E, Moran C, Taylor JM. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J. Biol. Chem. 2000;275:31567–31572
  39. Mahley RW, Rall SC. Type III hyperlipoproteinemia (dysbeta-lipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic basis of inherited disease. New York, NY: McGraw-Hill Publishing Co; 1989;p. 1195–1213
  40. Dallongeville J, Lussier-Cacan S, Davignon J. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J. Lipid Res. 1992;33:447–454

PII: S0021-9150(03)00139-4

doi: 10.1016/S0021-9150(03)00139-4

Atherosclerosis
Volume 169, Issue 1 , Pages 63-70 , July 2003

Article Tools